Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

Stephanie Russell, DNP, AGNP-C, highlights the importance of gender-neutral language in the oncology environment.

The median overall survival with intra-arterial gemcitabine was 15.7 months vs 10.1 months with intravenous gemcitabine and nab-paclitaxel.

Meghan K. Berkenstock, MD, discusses the growing need for strong collaboration between ophthalmologists and gynecologic oncology care teams.

Concurrent treatment with reirradiation and bevacizumab prolonged progression-free survival, but not overall survival, in patients with recurrent glioblastoma.

A study presented at the 2022 World Conference on Lung Cancer explored the experiences of patients who received checkpoint inhibition therapy for non–small cell lung cancer.

Powerful chemicals used in chemotherapy may pose safety hazards for oncology nurses, pharmacists, and other health care providers if not handled properly.

Frontline nivolumab and ipilimumab combination therapy was associated with increased 5-year survivorship in patients with metastatic non–small cell lung cancer—regardless of PD-L1 expression.

Nurses need to know which patients are at risk and the tools to use to diagnose cardiac toxicities.

Palliative care providers must, “lean into patient care in creative ways.”

A minimally invasive blood test has been found to be feasible to safely detect several types of cancers in patients without a history of malignancies.

New real-world data shows that PARP inhibitors have the potential to help patients with ovarian cancer and could be an affordable option for them.

Although we as healthcare providers want to be cautious and not provide a sense of false hope, we can also acknowledge that for individuals who are deeply religious and spiritual, terminal illness that results in death may not be viewed as negative.

Collaboration to feature content from one of nation’s leading nursing school programs.

Racial and ethnic minority populations in the United States continue to experience higher cancer mortality rates than those among non-minority populations.